Abstract
Objective
Insulin signalling via phosphoinositide 3-kinase (PI3K) requires PIK3R1-encoded regulatory subunits. C-terminal PIK3R1 mutations cause SHORT syndrome, as well as lipodystrophy and insulin resistance (IR), surprisingly without fatty liver or metabolic dyslipidaemia. We sought to investigate this discordance.
Methods
The human pathogenic Pik3r1 Y657∗ mutation was knocked into mice by homologous recombination. Growth, body composition, bioenergetic and metabolic profiles were investigated on chow and high-fat diet (HFD). We examined adipose and liver histology, and assessed liver responses to fasting and refeeding transcriptomically.
Results
Like humans with SHORT syndrome, Pik3r1WT/Y657∗ mice were small with severe IR, and adipose expansion on HFD was markedly reduced. Also as in humans, plasma lipid concentrations were low, and insulin-stimulated hepatic lipogenesis was not increased despite hyperinsulinemia. At odds with lipodystrophy, however, no adipocyte hypertrophy nor adipose inflammation was found. Liver lipogenic gene expression was not significantly altered, and unbiased transcriptomics showed only minor changes, including evidence of reduced endoplasmic reticulum stress in the fed state and diminished Rictor-dependent transcription on fasting. Increased energy expenditure, which was not explained by hyperglycaemia nor intestinal malabsorption, provided an alternative explanation for the uncoupling of IR from dyslipidaemia.
Conclusions
Pik3r1 dysfunction in mice phenocopies the IR and reduced adiposity without lipotoxicity of human SHORT syndrome. Decreased adiposity may not reflect bona fide lipodystrophy, but rather, increased energy expenditure, and we suggest that further study of brown adipose tissue in both humans and mice is warranted.
Keywords: Insulin resistance, Diabetes, Lipotoxicity, PI 3-Kinase, p85, Pik3r1, Lipids
Abbreviations: IR, insulin resistance; PI3K, phosphoinositide 3-kinase; SHORT syndrome, Short stature, Hyperextensibility of joints, Ocular depression, Rieger anomaly of the iris, and Teething delay; RER, Respiratory Exchange Ratio; HFD, High-Fat Diet
Highlights
-
•
SHORT syndrome features insulin resistance and reduced adiposity without dyslipidaemia and fatty liver.
-
•
A mouse model with a pathogenic human PI 3-Kinase mutation recapitulates this uncoupling.
-
•
Surprisingly, no adipose injury nor increased liver de novo lipogenesis is seen.
-
•
Energy expenditure is increased, causing resistance to diet-induced obesity.
-
•
This increases evidence for some beneficial metabolic effects of PI 3-Kinase inhibition.
1. Introduction
Adipose tissue is essential for metabolic health in the face of sustained positive energy balance. When adipose expansion is constrained, as in lipodystrophy, its capacity to sequester excess energy and serve as a physiological “energy buffer” is overwhelmed [1]. Injury and inflammation of any residual adipose tissue ensues, causing systemic inflammation and rerouting substrates to the liver, pancreas and muscle. Insulin resistance (IR), diabetes, aggressive fatty liver disease, and severely elevated plasma lipoprotein concentrations are thus common consequences of lipodystrophy [2].
SHORT syndrome (short stature, hyperextensibility of joints, ocular depression, Rieger anomaly of the iris, and teething delay) is a human monogenic syndrome including lipodystrophy [[3], [4], [5]]. This form of lipodystrophy is highly unusual - though associated with insulin resistant diabetes [[3], [4], [5]], this is uncoupled from fatty liver and dyslipidaemia [6]. SHORT syndrome also does not feature the suppressed plasma adiponectin concentration commonly seen in IR and other lipodystrophies [7], proving that some elements of the “insulin resistance syndrome” are dissociable.
SHORT syndrome is caused by mutations in PIK3R1; encoding components of the insulin signalling enzyme phosphoinositide 3-kinase (PI3K) [[3], [4], [5]]. The PI3K subtype required for insulin action comprises a p110α catalytic subunit bound to a regulatory subunit, three (p85α, p55α and p50α) of which are encoded by PIK3R1. PIK3R1 products stabilise catalytic subunits, mediating their recruitment to receptor tyrosine kinases or their substrates, including the insulin receptor and IRS1 [8,9].
Before the discovery of PIK3R1 mutations in SHORT syndrome, Pik3r1 had been intensively studied in mice. Selective p85α deficiency [10,11] or deletion of p50α and p55α [12] surprisingly enhances insulin sensitivity, which has been accounted for by compensation by other regulatory subunits, and/or altered stoichiometry of catalytic and regulatory subunits. A critical insight from the study of SHORT syndrome was that the insulin signalling role of PIK3R1 could be severely attenuated by neomorphic mutations disrupting the C-terminal SH2 domain [[3], [4], [5]]. Such dominant negative PIK3R1 alleles, which severely reduce insulin-induced activation of PI3K without abolishing the expression of PI3K, offer the opportunity to interrogate, more precisely than has been possible to date, the in vivo pathophysiological roles of PI3K activity in IR.
In human lipodystrophy, de novo lipogenesis contributes significantly to liver triglyceride and plasma lipid content [13]. In contrast, mutations in the INSR gene encoding the insulin receptor produce extreme IR with normal plasma lipid profile, normal liver lipid content, and no increase in hepatic de novo lipogenesis [13]. Furthermore, murine models with knockout of any one of several components of the insulin signalling pathway (Insr [14], Irs1 and Irs2 [15], p85α and β [16], Pik3ca [17], or Rictor [18]) demonstrate that liver insulin signalling drives hepatic de novo lipogenesis. We thus hypothesised that in SHORT syndrome, the liver is protected from increased insulin-mediated lipogenesis, which is relatively unaffected by common IR [19], and that this explains the absence of dyslipidaemia and fatty liver despite severe IR and lipodystrophy.
We report a novel murine SHORT syndrome model caused by a human pathogenic allele, Y657∗, that reproduces uncoupling of metabolic dyslipidaemia from severe IR. Surprisingly, hepatic lipogenic transcriptional programmes were minimally perturbed, although metabolic inflexibility with a dyscoordinated fasting response was seen. Adipose tissue accumulation was reduced on high-fat feeding. We suggest that this is related to increased energy expenditure, likely via brown adipose tissue, rather than lipodystrophy, with hypolipidemia attributable to increased fuel oxidation. This potential explanation for the unusual IR subphenotype of SHORT syndrome warrants testing in humans with SHORT syndrome or other proximal insulin signalling defects.
2. Materials and methods
2.1. Mice generation and maintenance
The Pik3r1 Y657∗ mutation and a neomycin resistance cassette flanked by LoxP sites were introduced into C57Bl/6 embryonic stem cells by homologous recombination before injection into Bl/6J blastocysts (Supplemental Figure S1). Animals were kept on a C57Bl/6J background, backcrossed at least three times, and housed on a 12-h-light/12-h-dark cycle at 23 °C, with ad libitum food and water access. Feeding was with chow (Catalogue no. 105, Safe diets) or 45% fat diet (45% fat, 35% Carbohydrate and 25% protein) (Catalogue no. D12451, Research diet, Inc). Experiments were carried out under the UK Home Office Animals (Scientific Procedures) Act 1986, following University of Cambridge ethical review.
2.2. Assessment of growth, body composition, and energy homeostasis
Body composition was determined by time-domain NMR with Bruker's minispec analyser. For food intake and energy expenditure measurement, male mice were acclimatized for 1 week to single housing then given chow or 45% fat diet for 10 days. Food intake was measured daily and energy expenditure measured by indirect calorimetry [20]. Locomotor activity was quantified as beam breaks over 48 h. Faecal energy content was measured by combusting dried faeces from 48 h calorimeter runs in an IKA Calorimeters Oxygen Bomb calorimeter (IKA C1).
2.3. In vivo metabolic studies
In fasting/refeeding studies, mice were fed chow ad libitum until 16 weeks of age before 16 h fasting, then 6 h refeeding with chow. Tissues were harvested and snap frozen prior to overnight fasting, or after fasting or after refeeding. For the study of insulin action, 16 h-fasted mice (16 weeks old) were injected with 2 U/kg insulin intraperitoneally and tissues collected after 10 min and snap frozen. Glucose tolerance testing was performed on overnight (16 h) fasted mice using 2 g/kg 20% glucose via oral gavage. Insulin tolerance testing was done by giving 0.5 U/kg intraperitoneal insulin to 6 h-fasted mice. For lipid tolerance testing, 16 h-fasted mice were administered 10 mL/kg olive oil by gavage.
Hyperinsulinemic euglycemic clamp studies and subsequent sample processing and analysis were conducted as described previously [21] on 16 week old mice after overnight fasting. The clamps used a priming dose of human insulin (0.7 mU), followed by constant insulin and [3-3H]-d-glucose infusion at 7 mU/h and 0.72 μCi/h, respectively.
2.4. Study of tissue insulin responsiveness ex vivo
Measurement of insulin action on isolated Soleus and Extensor Digitorum Longus was undertaken in 16-week-old male mice as described [22]. For primary preadipocyte differentiation studies, fat pads from 8 week-old male mice were isolated and cultured as described [20], but without 5-Triiodo-l-thyronine.
2.5. Biochemical assays
Blood was collected by cardiac puncture and plasma snap frozen before assays detailed in Supplemental Table 3. Glycogen hydrolysis in 1 M HCl (2.5 h at 100 °C), NaOH neutralization and fluorometric glucose analysis were used to determine the glycogen content of snap-frozen liver [23]. Hepatic triglyceride determination was used in the Triglyceride Colorimetric Assay kit (Cayman). Hepatic cholesterol was extracted from 10 mg of liver using a 400 μL chloroform:isopropanol:NP-40 mixture (7:11:0.1) before centrifugation, 30 min vacuum drying (50 °C) and dissolving in phosphate-buffered saline (PBS). The samples were assayed by Siemens Healthcare Diagnostics kit.
2.6. Metabolomic studies
Liver metabolites were extracted from tissue snap-frozen after dissection using a reported methanol/chloroform method [24]. Aqueous metabolites were further extracted as described in [24] and analysed using a Vanquish ultra-high performance liquid chromatography (UHPLC) system and TSQ Quantiva triple quadrupole mass spectrometer (Thermo Scientific) with compounds directly infused. Parameter optimisation used 1 μM standard solutions in a chromatographic buffer. Optimal mass spectrometry parameters and mass transitions were generated by automatic MassLynx™ (Version 1.4, Waters) protocols or, if standards were unavailable, deduced from known analogue parameters.
2.7. Assessment of de novo lipogenesis
Sixteen week chow-fed mice were fasted overnight, injected intraperitoneally with deuterated saline (24 μL/g), and given high carbohydrate diet (Harlan Teklad Diets, Cat no. TD88232) and 4% deuterated water (Goss Scientific Instruments Ltd, Cat no. DLM-2259) from 1 to 24 h later. Subsequent to culling, livers were snap-frozen and 50 mg homogenised in 600 μL methanol–chloroform (2:1) before extraction and analysis as described [25].
2.8. Histology
The sizes of at least 1000 adipocytes per genotype from 16-week-old chow-fed mice were measured in Formalin-fixed, paraffin-embedded (FFPE) tissue as described [26]. Adipose Treg cells were isolated and counted by FACS, also as reported [27].
2.9. Gene expression analysis
For protein studies fresh tissues were snap-frozen in liquid nitrogen, and homogenised using MD ceramic beads in RIPA buffer with proteinase/phosphatase inhibitors (liver, muscle) (Roche) or mortar and pestle in liquid nitrogen before dissolving in buffer (adipose). Protein concentrations were determined by BCA assay (BioRad). Western blotting employed the Novex gel system (Thermo Fisher Scientific). Antibodies are shown in Supplemental Table S4. Quantification employed the BioRad image system.
Total RNA was extracted and reverse transcribed for qPCR as previously described [28]. Target expression was normalised to the geometric mean of 4 housekeeping genes (Ywhaz, Ppia, B2m and Eef1a1) (Supplemental Table S4 for primer/probe sequences). RNA sequencing protocols and analysis have previously been reported [29].
2.10. Statistical analysis
D'Agostino & Pearson or Shapiro–Wilk tests were performed to test for Gaussian distribution of data. For Gaussian data, unpaired two-tailed Student's t tests for two group comparison and ANOVA with post hoc for multiple group comparison were performed using GraphPad Prism (GraphPad Software). For non-Gaussian data Mann–Whitney testing was used for two group comparison and Kruskal–Wallis and Dunn's multiple comparison testing were used for multiple group analysis using GraphPad Prism (GraphPad Software). Tissue weights, food consumption and energy expenditure were analysed by ANCOVA using XLSTAT (Addinsoft).
2.11. Data and resource availability
All transcriptomic data were deposited in GEO under accession number GSE153431. Other datasets, and the Pik3r1WT/Y657∗ mice generated during the current study are available from the corresponding author upon reasonable request.
3. Results
3.1. Growth and development of Pik3r1 Y657∗ knock-in mice
Mice harbouring the Pik3r1 Y657∗ mutation were generated by homologous recombination-based gene targeting (Figure S1A). Immunoblotting confirmed the expression of truncated p85α at greater amounts than full length protein in most tissues, likely due to the loss of an ubiquitylation motif located beyond the nonsense mutation in the C-terminal [30]. No compensatory change in PI3K p85β subunit was seen. p110α subunit expression was reduced in subcutaneous white adipose tissue, and p110β expression was reduced in liver, subcutaneous and epididymal white adipose tissue (Figure S1B).
No Pik3r1Y657∗/Y657∗ embryos were identified beyond E11.5. At E11.5 they were smaller, with poorly developed limb buds and reduced eye pigmentation. Heterozygous embryos were smaller from E15.5 (Figure S2A–E). Pik3r1WT/Y657∗ mice were born at the expected frequency, but showed impaired linear growth and body weight on chow (Figure 1A–C). At 16 weeks, there was a small decrease in whole body adiposity (Figure 1D), however, no difference was found in epididymal or inguinal white adipose nor interscapular brown adipose depot weights when lean mass was taken into account (Figure 1E–G). Plasma leptin concentrations were similar in male Pik3r1WT/Y657∗ and wild-type mice (3.3 ± 1.2 vs 2.6 ± 0.3 μg/L on fasting (n = 9,10; NS); 10.3 ± 2.2 vs 15.9 ± 3.9 μg/L on ad libitum feeding (n = 13,13; NS)). Liver weights were indistinguishable (Figure 1H), but hearts were heavier in Pik3r1WT/Y657∗ mice (Figure 1I). No difference in food consumption nor energy expenditure was seen at 16 weeks on chow (Figure 1J,K), however, the respiratory exchange ratio (RER) was higher during the light phase in Pik3r1WT/Y657∗ mice, blunting the circadian fluctuation (Figure 1L). Similar differences were seen between heterozygous and wild-type females for all variables assessed in both sexes.
3.2. Response of Pik3r1WT/Y657∗ mice to a high-fat diet
To assess whether placing a greater load on adipose tissue in Pik3r1WT/Y657∗ mice would unmask lipodystrophy, mice were fed a 45% fat diet (HFD) from 8 weeks old. mice showed reduced weight gain and body fat over the 8 weeks of study (Figure 2A,B). Epididymal white adipose tissue was most severely affected (Figure 2C), with no significant difference in inguinal nor brown adipose tissue (Figure 2D,E). Lean mass did not increase at a greater rate in Pik3r1WT/Y657∗ mice (Figure S3A,B), and liver weights also did not differ, while heart weights were elevated in heterozygotes, as on chow (Figure 2F,G). Consistent with reduced adiposity, Pik3r1WT/Y657∗ mice had lower serum leptin concentrations when fed (37.7 ± 7.3 vs 11.3 ± 2.0 μg/L (n = 15,11; p = 3 × 10−3)), but not when fasted (15.9 ± 3.9 vs 10.3 ± 2.2 μg/L (n = 13,13; not significant)), while adiponectin concentrations were unchanged (Table 1).
Table 1.
Chow |
45% Fat diet |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Fasting |
Fed |
Fasting |
Fed |
|||||||||
Pik3r1WT/WT (n = 10) | Pik3r1WT/Y657∗ (n = 9) | p | Pik3r1WT/WT (n = 10) | Pik3r1WT/Y657∗ (n = 14) | p | Pik3r1WT/WT (n = 13) | Pik3r1WT/Y657∗ (n = 13) | p | Pik3r1WT/WT (n = 15) | Pik3r1WT/Y657∗ (n = 11) | p | |
Glucose (mmol/L) | 10.2 ± 1.1 | 9.0 ± 1.1 | 0.43 | 12.5 ± 0.7 | 13.2 ± 0.5 | 0.48 | 9.7 ± 0.8 | 7.9 ± 0.5 | 0.06 | 12.6 ± 0.5 | 9.4 ± 0.5 | 4 × 10−4 |
Insulin (pmol/L) | 138 ± 21 | 603 ± 202 | 0.05 | 229 ± 33 | 3393 ± 578 | 1.9 × 10−4 | 469 ± 77 | 693 ± 102 | 0.09 | 424 ± 73 | 1313 ± 494 | 0.104 |
Adiponectin (mg/L) | 30.5 ± 1.1 | 26.7 ± 1.3 | 0.03 | 33.2 ± 1.5 | 35.6 ± 1.0 | 0.2 | 37.0 ± 1.1 | 40.6 ± 1.5 | 0.07 | 40.3 ± 2.2 | 42.8 ± 1.1 | 0.3 |
Total cholesterol (mmol/L) | 2.7 ± 0.1 | 2.3 ± 0.1 | 0.01 | 2.6 ± 0.1 | 2.0 ± 0.1 | 6 × 10−3 | 4.2 ± 0.2 | 3.0 ± 0.3 | 0.01 | 4.7 ± 0.3 | 1.7 ± 0.1 | 1.0 × 10−7 |
HDL cholesterol (mmol/L) | 1.5 ± 0.1 | 1.1 ± 0.1 | 0.02 | 1.6 ± 0.1 | 1.3 ± 0.1 | 0.04 | 1.8 ± 0.2 | 1.2 ± 0.2 | 0.02 | 2.3 ± 0.1 | 0.9 ± 0.1 | 2.7 × 10−8 |
Triglycerides (mmol/L) | 1.5 ± 0.1 | 1.0 ± 0.1 | 0.01 | 1.6 ± 0.1 | 1.1 ± 0.1 | 0.01 | 1.5 ± 0.1 | 1.4 ± 0.1 | 0.15 | 1.0 ± 0.1 | 0.6 ± 0.02 | 3.5 × 10−6 |
NEFA (mmol/L) | 2.0 ± 0.2 | 1.2 ± 0.1 | 5 × 10−3 | 1.5 ± 0.1 | 1.3 ± 0.2 | 0.3 | 2.5 ± 0.2 | 1.9 ± 0.1 | 0.05 | 1.5 ± 0.1 | 0.8 ± 0.1 | 7 × 10−5 |
VLDL (mg/mL) | N.D. | N.D. | N.D. | 7.9 ± 0.3 | 7.4 ± 1.2 | 0.25 | N.D. | N.D. | N.D. | 10.5 ± 0.5 | 11.9 ± 0.8 | 0.13 |
Given reduced adipose expansion, we subsequently sought histological evidence of “adipose failure”, namely adipocyte hypertrophy and inflammation, which would be expected in lipodystrophy when adipose expansion is pathologically constrained, causing adipose injury on positive energy balance. The histological appearance and adipocyte size distribution in epididymal adipose tissue was indistinguishable between genotypes (Figure 2H,I), however with no evidence of inflammation, nor fibrosis. Consistent with the lack of histological evidence of adipose overload, ex vivo differentiation of preadipocytes from inguinal or epididymal depots was unaltered (Figure 2J). Finally, given the role of Pik3r1 in lymphocyte function, and the important role of adipose-resident T regulatory (Treg) cells in energy homeostasis, the adipose content of Treg cells was assessed by FACS. No major difference was observed between genotypes (Figure 2K).
Given these findings, which are at odds with a true lipodystrophy, we then assessed whether reduced adipose accretion rather reflected altered energy homeostasis. Pik3r1WT/Y657∗ mice exhibited increased food intake (Figure 2L) and energy expenditure (Figure 2M) when the size of the animals was taken into account, but locomotor activity was unchanged across 24 h (Figure 2N). Markedly reduced accumulation of adipose tissue despite increased food intake, and without sustained hyperglycaemia, demonstrates severely reduced food efficiency. This indicates that increased food intake is a compensatory response to chronically increased energy expenditure rather than a primary phenomenon. As on chow, the circadian RER profile was blunted, with higher values in the dark phase and no discernible difference between light and dark phases for Pik3r1WT/Y657∗ mice (Figure 2O), suggesting greater carbohydrate oxidation in the dark phase.
3.3. Pik3r1WT/Y657∗ mice are severely insulin resistant
At 12 weeks old, neither male nor female Pik3r1WT/Y657∗ mice on chow were hyperglycaemic compared to controls, but plasma insulin concentrations were raised, more severely on feeding (Tables 1 and S1). On high-fat feeding, male Pik3r1WT/Y657∗ mice remained hyperinsulinemia, but the difference between mutant and control mice was abolished by the greater increase in insulin concentrations in wild-type mice. Blood glucose concentration was paradoxically lower in fed Pik3r1WT/Y657∗ mice on HFD. Plasma adiponectin concentrations in fasted chow-fed Pik3r1WT/Y657∗ mice were lower than in wild-type controls, however no significant difference was seen in other conditions, despite the severe IR of heterozygous mice (Table 1). In Pik3r1WT/Y657∗ mice on HFD, adiponectin normalised to body fat was higher than in controls, reminiscent of the preserved adiponectin seen in severely insulin-resistant patients with SHORT syndrome [7]. Normalised plasma leptin concentrations, in contrast, were lower (Figure S3C,D).
Hyperinsulinemic euglycemic clamps were undertaken on chow- and HFD-fed male mice. Chow-fed Pik3r1WT/Y657∗ mice required a steady state glucose infusion rate of only one eighth that required by wild-type mice, confirming severe IR (Figure 3A). On HFD, Pik3r1WT/Y657∗ mice remained extremely insulin resistant, however the difference between genotypes was much smaller than on chow due to increased IR in wild-type animals (Figure 3A). Further studies were thus carried out on chow. Glucose and insulin excursions on oral glucose tolerance testing showed a trend towards an increase in male Pik3r1WT/Y657∗ mice (Figure 3B,C), but were increased in female mice (Figure S4A,B), while the hypoglycaemic response to insulin was attenuated in both sexes (Figures 3D and S4C). Clamp studies in males using isotopic tracers showed glucose disposal to be 19% lower in Pik3r1WT/Y657∗ mice (Figure 3E) while suppression of hepatic glucose production by hyperinsulinemia was 49% lower compared to wild type littermates (Figure 3F). Liver glycogen content was similar between genotypes (Figure 3G). Insulin infusion lowered plasma free fatty acid concentrations in wild-type mice, but little suppression was seen in heterozygous mice, consistent with impaired suppression of adipose lipolysis (Figure 3H).
Intraperitoneal insulin in male mice strongly induced Akt phosphorylation in the liver, skeletal muscle and epididymal and inguinal adipose tissue of wild-type controls, as expected, and this was reduced in Pik3r1WT/Y657∗ mice (Figures 3I–L and S5A–D). As muscle insulin sensitivity was previously reported not to be reduced in Pik3r1WT/R649W mice [31], insulin responsiveness of soleus and extensor digitorum longus (EDL) muscles was assessed ex vivo. Soleus and EDL muscle from Pik3r1WT/Y657∗ mice both showed a 1.3-fold reduction in insulin-stimulated deoxyglucose uptake compared to wild-type muscle (Figure 3M). Insulin-induced Akt phosphorylation was also markedly reduced in both types of muscle ex vivo to a much more significant degree than in vivo (Figures 3N,O and S5E). This finding of muscle insulin resistance using several techniques, although contrasting with clamp studies reported previously, is consistent with the robust expression of Pik3r1 gene products in skeletal muscle.
3.4. Pik3r1WT/Y657∗ mice are hypolipidemic
Having demonstrated that, as in SHORT syndrome, heterozygous Pik3r1WT/Y657∗ mice show severe IR and reduced adiposity, we assessed whether, like humans, they do not exhibit fatty liver nor metabolic dyslipidaemia. In fed and fasting states, on either chow or HFDs, Pik3r1WT/Y657∗ mice showed hypolipidemia, with lower plasma total cholesterol and HDL cholesterol (Table 1). This was most striking in fed mice on HFD, mirroring the lower glucose seen in Pik3r1WT/Y657∗ mice in this state. Plasma triglyceride concentrations were also lower in heterozygous animals in all states except when the fasting state after HFD. Plasma free fatty acid concentrations were lower in all states except in fed animals maintained on chow. Similar hypolipidemia was seen in chow-fed female mice on fasting (Table S1). No difference was seen in VLDL concentrations in chow- or high fat-fed mice (Table 1).
Despite severe IR in Pik3r1WT/Y657∗ mice, no difference was seen in liver triglyceride content compared to controls either on chow or HFD, assessed by Oil-Red-O staining and biochemical quantification (Figure 4A,B). Liver cholesterol content was also the same in chow-fed animals of both genotypes (Figure 4C). Oral lipid tolerance testing revealed similar triglyceride excursion after lipid loading in both genotypes (Figure 4D), and bomb calorimetry of faeces on chow showed the same energy content (Figure 4E), excluding abnormal intestinal lipid handling as the explanation for hypolipidemia and reduced adiposity.
Insulin stimulates hepatic de novo lipogenesis and cholesterogenesis via Srebp1 and Srebp2 respectively. In prevalent IR, hepatic de novo lipogenesis is enhanced, and the mismatch between this and the reduced hypoglycaemic action of insulin is evidence for “partial IR” in metabolic dyslipidaemia [19]. Liver PI3K mediates the action of insulin on lipogenesis, with hypolipidemia despite IR seen in numerous models in which hepatic insulin/Irs/PI3K/Akt2/mTORC2 signalling is impaired [[14], [15], [16],18,32]. Based on these findings, we hypothesised that the hypolipidemia seen in Pik3r1WT/Y657∗ mice would be accounted for by reduced hepatic de novo lipogenesis, as in SHORT syndrome due to PIK3R1 Y657∗ [7]. In keeping with this, no increased de novo synthesis of palmitate could be measured in heterozygotes despite fasting hyperinsulinemia and refeeding with a high carbohydrate diet (Figure 4F). Liver mRNA expression of Srebp1c, Srebp2 and key target genes (Acc1, Fasn, Scd1 and Mvk, Nsdhl, respectively) was also determined in chow-fed animals in fed, fasting and refed states, and no difference was seen in the expression of any of these genes under any nutritional conditions (Figure 4G–M).
Other transcriptional regulators relevant to hypolipidemia include carbohydrate response element binding protein (Chrebp) and Xbp1, with the latter binding p85α and facilitating its nuclear translocation [31,33,34]. A sentinel Chrebp-responsive gene (Pklr) showed mild but significant reduction of mRNA in the fasting state, but mRNA of two Xbp1 target genes (Acacb and Dgat2) showed no reduction during a fasting refeeding cycle (Figure S6A–C). It has also been proposed that modulation of the ratio between Glucose-6-phosphatase (G6pc) and Glucokinase (Gck) toggles hepatocyte glucose flux between lipogenesis and glucose production, and that this operates before transcriptional changes in lipogenic transcription factors [35]. However, although an increase in G6pc:Gck liver transcript levels was seen on fasting of wild-type mice, the ratio was suppressed in Pik3r1WT/Y657∗ mice, as reported in mice on Western-type diet [35] (Figure S6D–F). We conclude that the consistent hypolipidemia seen in Pik3r1WT/Y657∗ mice does not correlate with reduced insulin-induced lipogenesis in the liver, suggesting that the reduced blood lipid concentrations are not explained by attenuation of insulin's lipogenic actions.
Given the lack of transcriptional perturbation of known lipogenic factors, global liver transcriptomic analysis was performed in fed and 16 h fasted states. Genotypes were compared in each state, and fasting gene expression was compared to fed gene expression for both genotypes. Gene-based analysis confirmed prior findings, but provided no obvious alternative explanation for hypolipidemia. Pathway analysis of predicted upstream regulators showed modest but significant differences in the fed state, with a transcriptional signature of reduced Endoplasmic Reticulum (ER) stress (upstream regulators Xbp1, its processing enzyme Ern1 (Ire1), and Atf6), and altered signatures of several cytokines including IL6 (reduced), IL21, interferons gamma and alpha 2 (increased) (Figure 5, Table S2). More significant differences were seen after 16-h fasting, when a transcriptional profile consistent with the reduced activity of Rictor, the defining component of mTORC2, was seen with high significance, while patterns associated with Myc and Mycn were upregulated. The large preponderance of changes observed between fed and fasting states in wild-type mice, including strong upregulation of PPARα-responsive genes, was however conserved in heterozygous animals (Figure 5, Table S2).
In view of the transcriptomic evidence of reduced Rictor activity, plasma and hepatic amino acid and β-hydroxybutyrate concentrations were determined. This revealed increased β-hydroxybutyrate in the liver from fed Pik3r1WT/Y657∗ mice with a trend towards an increase in plasma, but no difference between genotypes when fasted (Figure S7A). The fall in plasma amino acid concentrations seen in fasting wild-type mice was lost in Pik3r1WT/Y657∗ mice, with a trend towards a generalised increase in liver amino acids (Figure S7B,C). These findings add to the evidence for abnormal transitions between fed and fasted states in Pik3r1WT/Y657∗ mice, and suggest that reduced intra-hepatocyte amino acid concentrations on fasting do not explain the pronounced reduction in Rictor signalling suggested by transcriptomics.
4. Discussion
Most monogenic defects causing severe IR primarily affect adipose tissue development, and metabolically phenocopy common IR [1]. In contrast, humans with severe IR due to proximal insulin signalling defects do not have the dyslipidaemia, fatty liver, nor decreased plasma adiponectin concentration usual in common IR [6,7,13,36]. This was first noted in people with insulin receptor mutations [13], but more recently, has been described in SHORT syndrome [6,7], in which the lack of fatty liver and dyslipidaemia is particularly striking given concomitant lipodystrophy. Fatty liver and atherogenic dyslipidaemia are major sources of IR-related morbidity, so investigating how these are dissociated from IR in the face of proximal insulin signalling defects will potentially reveal novel approaches to mitigate IR-associated disease.
The novel mice generated, heterozygous for the Pik3r1 Y657∗ allele, show reduced growth, severe IR, and severely reduced adipose accretion on high-fat feeding. Although IR in Pik3r1R649W/WT mice described previously was reported to spare skeletal muscle [31], we found skeletal muscle to be insulin resistant both in clamps, and ex vivo, in keeping with the ubiquitous expression of the mutant allele.
Despite severe IR, Pik3r1WT/Y657∗ mice were hypolipidemic on chow or HFD, and in fed and fasted states, while the increase in liver triglyceride usual in lipodystrophic IR was absent, validating it as a model of the human phenomenon we aimed to study. Knockout evidence that PI3K signalling mediates insulin's stimulation of liver de novo lipogenesis led us to expect reduced transcript levels of Srebp and its target genes (e.g. [16,17]), however we found no evidence supporting this or other candidate transcriptional mechanisms including reduced lipogenic activity of Xbp1 [34].
RNA sequencing showed most insulin-responsive genes to respond normally to fasting and refeeding. Given elevated plasma insulin concentrations, this could be construed as showing compensated hepatic IR, as expected from a proximal insulin signalling defect. Fasting-responsive programmes, such as those orchestrated by PPARα, were intact in Pik3r1WT/Y657∗ mice, however pathway analysis suggested reduced ER stress signalling and showed altered inflammatory signatures in the fed state, with a strikingly reduced Rictor signature in the fasted state. These transcriptional clues may be pertinent to the protection from dyslipidaemia as ER stress signalling promotes fatty liver and dyslipidaemia [37], while Rictor drives hepatic lipogenesis [38], however further study is needed. Impaired induction of Rictor activity in this case may reflect Pik3r1's role in amino acid activation of Rictor [39].
Pik3r1R649W/WT mice have been shown to have less subcutaneous adipose tissue [31] and reduced adipose expansion in obesogenic conditions [40], as in the current report, which was interpreted as evidence of lipodystrophy. However, constrained adipose expansion produces inflammation of overloaded, hypertrophic adipose tissue during chronic positive energy balance [1], and the normal adipocyte appearance, lack of adipose inflammation, and normal differentiation of preadipocytes ex vivo in both studies argue against this [31].
Reduced adipose mass can reflect altered energy balance rather than lipodystrophy. Reduction of PI3K pathway activity by overexpression of the lipid phosphatase Pten in mice was previously reported to enhance energy expenditure via brown adipose tissue activation [41], albeit without IR, while pharmacological or genetic inhibition of the p110α catalytic subunit of PI3K has also been associated with increased energy expenditure [[40], [41], [42], [43]]. Moreover, a similar energetic phenotype on brown adipose-specific knockout of Pik3r1 has recently been described [44]. On HFD we found that food intake and energy expenditure were both increased in Pik3r1WT/Y657∗ mice. Given unaltered locomotor activity, intestinal lipid absorption, and lean tissue growth, reduced adipose accumulation shows that increased energy expenditure outweighed increased food intake, and is thus the primary abnormality. Reduced thermal insulation in smaller animals is an unlikely explanation [43]; hence, we conclude that increased energy expenditure explains reduced adipose accretion. Increased brown adipose tissue activity is the most likely explanation, as in models with p110α inhibition [[40], [41], [42], [43]], but this requires further study.
Increasing brown adipose tissue function reduces plasma triglyceride and cholesterol concentrations [45,46], and this reduces atherogenesis when liver scavenging of triglyceride-depleted lipoproteins is intact [45]. This accords with the hypolipidemia of Pik3r1WT/Y657∗ mice, and humans with SHORT syndrome. As brown fat is now known to occur in humans, it would be of interest to establish whether it is hyperactive in people with SHORT syndrome. In addition, given the normal lipid profile despite severe IR in people with insulin receptor mutations [13], and the reduced adipose tissue in mice harbouring a common dominant negative insulin receptor allele on an obesogenic diet [47], it will be of interest to assess whether the bioenergetic consequences of reduced PI3K signalling are also seen in the face of insulin receptor dysfunction.
5. Conclusions
We report a novel mouse model of SHORT syndrome recapitulating the severe IR without dyslipidaemia seen in humans. Hepatic lipogenesis and lipogenic gene expression were unimpaired, and transcriptomic pathway analysis suggested only mild nutritional state-specific abnormalities in liver gene expression. White adipose tissue was reduced on HFD, but did not show inflammation of hypertrophy, while energy expenditure was increased, raising the testable possibility that the reduced adipose mass in SHORT syndrome does not represent true “lipodystrophy”. The most likely mechanism explaining uncoupling of IR from dyslipidaemia in SHORT syndrome is increased brown adipose activity, consistent with other murine evidence that inhibition of PI3K results in beneficial metabolic alterations as well as IR.
Author contributions
Conceptualization, RKS, AK; Methodology, SV, AK, PV, IZ, JJ, JG, JW, RA Formal Analysis, AK, IZ, SV, IHD, PT, DAB, DH, RK, PV, JG, JW, JJ, RKS; Investigation, AK, IZ, SV, IL, IHD, PT, DAB, DH, RK, PV, JJ, RKS; Writing – Original Draft, RKS, AK, IHD; Writing – Review & Editing, IZ, SV, PT, DAB, DH, RK, AVP, PV, JJ, SO; Supervision, RKS; Project Administration, RKS; Funding Acquisition, RKS, SO, AVP.
Acknowledgements
RKS is the guarantor of this work, had full access to study data and takes responsibility for data integrity and accuracy of data analysis. The authors have declared that no conflict of interest exists. Parts of this work have been presented at scientific conferences (Keystone symposium, January 2018) and a previous version of the manuscript was deposited at bioRxiv (224485). RKS and SO were supported by the Wellcome Trust [grants 210752/Z/18/Z and WT095515 respectively], and by the Medical Research Council (MRC) [grant MC_UU_12012/5]. AVP and SV were funded by the British Heart Foundation [grant RG/18/7/33636] and the MRC [MC_UU_12012/2]. Animal work was conducted in the MRC Disease Model Core [MC_UU_12012/5]. We are grateful for technical assistance from Amy Warner at the MRC Disease Model Core, Keith Burling at the MRC MDU Mouse Biochemistry Laboratory, James Warner at the Histology Core Facility and Davide Chiarugi, Brian Lam and Marcella Ma at the IMS-BIO2 Core Facility, all funded by the MRC (MRC_MC_UU_12012/5). We thank Gregory Strachan at the Imaging Core Facility, funded by the Wellcome Trust [Grant 100574/Z/12/Z].
Footnotes
Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2020.101020.
Conflict of interest
The authors declare no conflicts of interest.
Appendix A. Supplementary data
The following is the supplementary data to this article:
References
- 1.Mann J.P., Savage D.B. What lipodystrophies teach us about the metabolic syndrome. Journal of Clinical Investigation. 2019;130 doi: 10.1172/jci129190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Leiter S.M., Semple R.K. vol. 25. 2017. Insulin resistance and diabetes associated with lipodystrophies; pp. 119–133. (Diabetes associated with single gene defects and chromosomal abnormalities). [Google Scholar]
- 3.Chudasama K.K., Winnay J., Johansson S., Claudi T., König R., Haldorsen I. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. American Journal of Human Genetics. 2013;93(1):150–157. doi: 10.1016/j.ajhg.2013.05.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Dyment D.A., Smith A.C., Alcantara D., Schwartzentruber J.A., Basel-Vanagaite L., Curry C.J. Mutations in PIK3R1 cause SHORT syndrome. American Journal of Human Genetics. 2013;93(1):158–166. doi: 10.1016/j.ajhg.2013.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Thauvin-Robinet C., Auclair M., Duplomb L., Caron-Debarle M., Avila M., St-Onge J. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. American Journal of Human Genetics. 2013;93(1):141–149. doi: 10.1016/j.ajhg.2013.05.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Avila M., Dyment D.A., Sagen J.V., St-Onge J., Moog U., Chung B.H.Y. Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management. Clinical Genetics. 2016;89(4):501–506. doi: 10.1111/cge.12688. [DOI] [PubMed] [Google Scholar]
- 7.Huang-Doran I., Tomlinson P., Payne F., Gast A., Sleigh A., Bottomley W. Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations. JCI Insight. 2016;1(17) doi: 10.1172/jci.insight.88766. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Vanhaesebroeck B., Stephens L., Hawkins P. PI3K signalling: the path to discovery and understanding. Nature Reviews Molecular Cell Biology. 2012;13(3):195–203. doi: 10.1038/nrm3290. [DOI] [PubMed] [Google Scholar]
- 9.Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–1657. doi: 10.1126/science.296.5573.1655. [DOI] [PubMed] [Google Scholar]
- 10.Terauchi Y., Tsuji Y., Satoh S., Minoura H., Murakami K., Okuno a. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nature Genetics. 1999;21(2):230–235. doi: 10.1038/6023. [DOI] [PubMed] [Google Scholar]
- 11.Mauvais-Jarvis F., Ueki K., Fruman D.A., Hirshman M.F., Sakamoto K., Goodyear L.J. Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. Journal of Clinical Investigation. 2002;109(1):141–149. doi: 10.1172/JCI13305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Chen D., Mauvais-Jarvis F., Bluher M., Fisher S.J., Jozsi A., Goodyear L.J. p50/p55 phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Molecular and Cellular Biology. 2004;24(1):320–329. doi: 10.1128/MCB.24.1.320-329.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Semple R.K., Sleigh A., Murgatroyd P.R., Adams C.A., Bluck L., Jackson S. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. Journal of Clinical Investigation. 2009;119(2):315–322. doi: 10.1172/JCI37432. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Biddinger S.B., Hernandez-Ono A., Rask-Madsen C., Haas J.T., Alemán J.O., Suzuki R. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metabolism. 2008;7(2):125–134. doi: 10.1016/j.cmet.2007.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kubota N., Kubota T., Itoh S., Kumagai H., Kozono H., Takamoto I. Dynamic functional relay between insulin receptor substrate 1 and 2 in hepatic insulin signaling during fasting and feeding. Cell Metabolism. 2008;8(1):49–64. doi: 10.1016/j.cmet.2008.05.007. [DOI] [PubMed] [Google Scholar]
- 16.Taniguchi C.M., Kondo T., Sajan M., Luo J., Bronson R., Asano T. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKCλ/ζ. Cell Metabolism. 2006;3(5):343–353. doi: 10.1016/j.cmet.2006.04.005. [DOI] [PubMed] [Google Scholar]
- 17.Sopasakis V.R., Liu P., Suzuki R., Kondo T., Winnay J., Tran T.T. Specific roles of the p110α isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metabolism. 2010;11(3):220–230. doi: 10.1016/j.cmet.2010.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hagiwara A., Cornu M., Cybulski N., Polak P., Betz C., Trapani F. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metabolism. 2012;15(5):725–738. doi: 10.1016/j.cmet.2012.03.015. [DOI] [PubMed] [Google Scholar]
- 19.Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metabolism. 2008:95–96. doi: 10.1016/j.cmet.2007.12.009. [DOI] [PubMed] [Google Scholar]
- 20.Whittle A.J., Jiang M., Peirce V., Relat J., Virtue S., Ebinuma H. Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans. Nature Communications. 2015;6:8951. doi: 10.1038/ncomms9951. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Schreiber R., Hofer P., Taschler U., Voshol P.J., Rechberger G.N., Kotzbeck P. Hypophagia and metabolic adaptations in mice with defective ATGL-mediated lipolysis cause resistance to HFD-induced obesity. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(45):13850–13855. doi: 10.1073/pnas.1516004112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Sell H., Jensen J., Eckel J. Measurement of insulin sensitivity in skeletal muscle in vitro. Methods in Molecular Biology. 2012;933:255–263. doi: 10.1007/978-1-62703-068-7. [DOI] [PubMed] [Google Scholar]
- 23.Lowry O.H., Passonneaau J.V. Academic Press; 1972. A flexible system of enzyme analysis. [Google Scholar]
- 24.Horscroft J.A., Kotwica A.O., Laner V., West J.A., Hennis P.J., Levett D.Z.H. Metabolic basis to Sherpa altitude adaptation. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(24):6382–6387. doi: 10.1073/pnas.1700527114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Roberts L.D., Virtue S., Vidal-Puig A., Nicholls A.W., Griffin J.L., Bethell D. Metabolic phenotyping of a model of adipocyte differentiation. Physiological Genomics. 2009;39(2):109–119. doi: 10.1152/physiolgenomics.90365.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Virtue S., Feldmann H., Christian M., Tan C.Y., Masoodi M., Dale M. A new role for lipocalin prostaglandin D synthase in the regulation of brown adipose tissue substrate utilization. Diabetes. 2012;61(12):3139–3147. doi: 10.2337/db12-0015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Mauro C., Smith J., Cucchi D., Coe D., Fu H., Bonacina F. Obesity-induced metabolic stress leads to biased effector memory CD4+ T cell differentiation via PI3K p110δ-Akt-mediated signals. Cell Metabolism. 2017;25(3):593–609. doi: 10.1016/j.cmet.2017.01.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Larder R., Sim M.F.M., Gulati P., Antrobus R., Tung Y.C.L., Rimmington D. Obesity-associated gene TMEM18 has a role in the central control of appetite and body weight regulation. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(35):9421–9426. doi: 10.1073/pnas.1707310114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Rocha N., Bulger D.A., Frontini A., Titheradge H., Gribsholt S.B., Knox R. Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression. ELife. 2017;6 doi: 10.7554/elife.23813. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Ko H.R., Kim C.K., Lee S.B., Song J., Lee K.-H., Kim K.K. P42 Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP. Cell Death & Disease. 2014;5(3):e1131. doi: 10.1038/cddis.2014.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Winnay J.N., Solheim M.H., Dirice E., Sakaguchi M., Noh H.L., Kang H.J. PI3-kinase mutation linked to insulin and growth factor resistance in vivo. Journal of Clinical Investigation. 2016;126(4):1401–1412. doi: 10.1172/JCI84005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Leavens K.F., Easton R.M., Shulman G.I., Previs S.F., Birnbaum M.J. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metabolism. 2009;10(5):405–418. doi: 10.1016/j.cmet.2009.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Park S.W., Zhou Y., Lee J., Lu A., Sun C., Chung J. The regulatory subunits of PI3K, p85α and p85β, interact with XBP-1 and increase its nuclear translocation. Nature Medicine. 2010;16(4):429–437. doi: 10.1038/nm.2099. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lee A.-H., Scapa E.F., Cohen D.E., Glimcher L.H. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science. 2008;320(5882):1492–1496. doi: 10.1126/science.1158042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Haeusler R.A., Hartil K., Vaitheesvaran B., Arrieta-Cruz I., Knight C.M., Cook J.R. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nature Communications. 2014;5:5190. doi: 10.1038/ncomms6190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Semple R.K., Soos M.A., Luan J., Mitchell C.S., Wilson J.C., Gurnell M. Elevated plasma adiponectin in humans with genetically defective insulin receptors. Journal of Clinical Endocrinology and Metabolism. 2006;91(8):3219–3223. doi: 10.1210/jc.2006-0166. [DOI] [PubMed] [Google Scholar]
- 37.Wang L., Chen J., Ning C., Lei D., Ren J. Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic fatty liver disease (NAFLD) Current Drug Targets. 2018;19 doi: 10.2174/1389450118666180516122517. [DOI] [PubMed] [Google Scholar]
- 38.Yuan M., Pino E., Wu L., Kacergis M., Soukas A.A. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. Journal of Biological Chemistry. 2012;287(35):29579–29588. doi: 10.1074/jbc.M112.386854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Tato I., Bartrons R., Ventura F., Rosa J.L. Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. Journal of Biological Chemistry. 2011;286(8):6128–6142. doi: 10.1074/jbc.M110.166991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Solheim M.H., Winnay J.N., Batista T.M., Molven A., Njølstad P.R., Kahn C.R. Mice carrying a dominant-negative human PI 3-kinase mutation are protected from obesity and hepatic steatosis but not diabetes. Diabetes. 2018;67(7):db171509. doi: 10.2337/db17-1509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ortega-Molina A., Efeyan A., Lopez-Guadamillas E., Muñoz-Martin M., Gómez-López G., Cañamero M. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metabolism. 2012;15(3):382–394. doi: 10.1016/j.cmet.2012.02.001. [DOI] [PubMed] [Google Scholar]
- 42.Araiz C., Yan A., Bettedi L., Samuelson I., Virtue S., McGavigan A.K. Enhanced β-adrenergic signalling underlies an age-dependent beneficial metabolic effect of PI3K p110α inactivation in adipose tissue. Nature Communications. 2019 Apr 4;10(1):1546. doi: 10.1038/s41467-019-09514-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Fischer A.W., Csikasz R.I., von Essen G., Cannon B., Nedergaard J. No insulating effect of obesity. American Journal of Physiology – Endocrinology and Metabolism. 2016;311(1):E202–E213. doi: 10.1152/ajpendo.00093.2016. [DOI] [PubMed] [Google Scholar]
- 44.Gomez-Hernandez A., Lopez-Pastor A.R., Rubio-Longas C., Majewski P., Beneit N., Viana-Huete V. Specific knockout of p85α in brown adipose tissue induces resistance to high-fat diet–induced obesity and its metabolic complications in male mice. Molecular Metabolism. 2020;31:1–13. doi: 10.1016/j.molmet.2019.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Berbeé J.F.P., Boon M.R., Khedoe P.P.S.J., Bartelt A., Schlein C., Worthmann A. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nature Communications. 2015;6:6356. doi: 10.1038/ncomms7356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Dong M., Yang X., Lim S., Cao Z., Honek J., Lu H. Cold exposure promotes atherosclerotic plaque growth and instability via UCP1-dependent lipolysis. Cell Metabolism. 2013;18(1):118–129. doi: 10.1016/j.cmet.2013.06.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Lee E.Y., Sakurai K., Zhang X., Toda C., Tanaka T., Jiang M. Unsuppressed lipolysis in adipocytes is linked with enhanced gluconeogenesis and altered bile acid physiology in Insr(P1195L/+) mice fed high-fat-diet. Scientific Reports. 2015;5:17565. doi: 10.1038/srep17565. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.